Teva Pharma

Teva Pharm reports progress on its 'Pivot to Growth' strategy pursued since 2023 and sees increasing momentum despite price pressure in the generics business. Commercial wins: AUSTEDO reached a $2.5 billion annual sales target one year early, AJOVY exceeded $1 billion, and UZEDY leads the US market for long-acting risperidone injections. The company targets $800 million in biosimilars sales by the end of 2027, highlights strong pipeline candidates such as Duvakitug and Ecopipam, and cites its large US manufacturing base as a strategic advantage. Management notes that future launches will depend on pricing and market access, particularly Medicaid/Medicare. » Więcej na de.investing.com

Teva Pharm has issued a package of senior, unsecured notes totaling about $4.9 billion in five tranches across three jurisdictions. The offerings include €1 billion (coupon 4.25%, maturity 2033), €500 million (4.625%, 2036), two $1 billion U.S. tranches (5.50% due 2034 and 5.75% due 2037) and $1.2 billion (5.25%, 2032). Teva intends to use the net proceeds together with cash on hand to repay certain existing bonds, to cover fees and expenses, and for general corporate purposes; settlement is planned for around 16 September 2026. » Więcej na de.investing.com

Teva Pharm reports a clear success in a phase‑2a study of the anti‑interleukin‑15 antibody TEV ’408 for the treatment of celiac disease: the primary endpoint was met and at week 8 the drug showed a statistically significant and clinically meaningful prevention of gluten‑induced intestinal damage with a good tolerability profile. TEV ’408 is also being tested in a phase‑2b study for vitiligo and was developed in collaboration with Royalty Pharma, which has pledged up to USD 500 million for clinical development. The news triggered an approximately 3.3% premarket share price increase and bolsters Teva Pharm’s pipeline story ahead of further corporate milestones. » Więcej na de.investing.com